DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2)

BACKGROUND: DaxibotulinumtoxinA for Injection (DAXI) is a novel botulinum toxin type A formulation in clinical development. A phase 2 dose-ranging study identified an optimal dose and demonstrated efficacy with a median duration of 24 weeks. METHODS: In two phase 3, multicenter, randomized, double-b...

Descripción completa

Detalles Bibliográficos
Autores principales: Carruthers, Jean D., Fagien, Steve, Joseph, John H., Humphrey, Shannon D., Biesman, Brian S., Gallagher, Conor J., Liu, Yan, Rubio, Roman G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Cosmetic: Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940025/
https://www.ncbi.nlm.nih.gov/pubmed/31609882
http://dx.doi.org/10.1097/PRS.0000000000006327

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940025/
https://www.ncbi.nlm.nih.gov/pubmed/31609882
http://dx.doi.org/10.1097/PRS.0000000000006327

Ejemplares similares